Sort
23,748 grants matching “melanoma”
Project 5: Microenvironment manipulation using anti-angiogenics to improve immunotherapy in melanoma
$276,920Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · P50 · FY2025 · CA
Core C - Biostatistics & Bioinformatics Core
$276,911Yongzhao Shao · New York University School Of Medicine · P50 · FY2021 · CA
Proliferative effects of cdk4 and cdk6 dysregulation
$276,838Philip W Hinds · Tufts Medical Center · R01 · FY2006 · CA
Etiologic Studies of Diet and Cancer
$276,819Neal Freedman · Division Of Cancer Epidemiology And Genetics · ZIA · FY2018 · CA
Structural basis for RIG-I and MDA-5 mediated antiviral response
$276,801Karl-Peter Hopfner · University Of Southern California · U19 · FY2012 · AI
CORE--MELANOMA FACILITY
$276,694University Of Pennsylvania · P30 · FY2000 · CA
CORE--MELANOMA FACILITY
$276,694University Of Pennsylvania · P30 · FY2001 · CA
CORE--CANCER PHARMACOLOGY BIOANALYTICAL FACILITY
$276,694University Of Pennsylvania · P30 · FY2001 · CA
CORE--CANCER PHARMACOLOGY BIOANALYTICAL FACILITY
$276,694University Of Pennsylvania · P30 · FY2000 · CA
CORE--CLINICAL RESEARCH UNIT
$276,694University Of Pennsylvania · P30 · FY2001 · CA
CORE--CLINICAL RESEARCH UNIT
$276,694University Of Pennsylvania · P30 · FY2000 · CA
Peptide-amphiphile biomimetics for targeted therapies
$276,675Gregg B Fields · University Of Texas Hlth Science Center · R01 · FY2008 · EB
Project 3: Translational Studies and Clinical Pharmacology of TLR4 and TOPK Signaling Pathway Inhibitors for Prevention of Squamous Cell Carcinoma of the Skin
$276,641Clara Curiel-Lewandrowski · University Of Arizona · P01 · FY2020 · CA
Clinical Development of anti-OX40 and OX40L
$276,600Brendan D Curti · Providence Portland Medical Center · R01 · FY2007 · CA
Clinical Development of anti-OX40 and OX40L
$276,599Brendan D Curti · Providence Portland Medical Center · R01 · FY2008 · CA
Augmenting the Immunogenicity of Melanoma Through Manipulation of Histone Deacet
$276,508Eduardo M Sotomayor · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2014 · CA
Core B: Proteomics Core.
$276,503Peter Kent Jackson · Stanford University · P01 · FY2022 · CA
Adhesion Regulation of ERK Trafficking to the Nucleus
$276,500Albany Medical College · R01 · FY2005 · GM
Keratinocyte responses to vascular endothelial growth factor in carcinogenesis
$276,450Traci A Wilgus · Ohio State University · R01 · FY2011 · CA
Keratinocyte responses to vascular endothelial growth factor in carcinogenesis
$276,450Traci A Wilgus · Ohio State University · R01 · FY2012 · CA
Enhanced MR reporter for immuno-imaging.
$276,406Jeff W Bulte · Johns Hopkins University · P41 · FY2017 · EB
Augmenting the Immunogenicity of Melanoma Through Manipulation of Histone Deacet
$276,404Eduardo M Sotomayor · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2013 · CA
SERUM CYT-MAA AS AN EARLY MARKER OF RESPONSE TO THERAPY IN RESECTED MELANOMA
$276,378Jean-Claude Bystryn · New York University School Of Medicine · R21 · FY2007 · CA
Cell-Cell Communication During Melanoma Development
$276,316Meenhard Herlyn · Wistar Institute · R01 · FY2010 · CA
Photothermal Sensitization of Biological Systems
$276,285Bowling Green State Univ Bowling Green · R01 · FY2001 · CA